JP7011600B2 - 被験体の免疫状態をモニタリングするための改善された方法 - Google Patents

被験体の免疫状態をモニタリングするための改善された方法 Download PDF

Info

Publication number
JP7011600B2
JP7011600B2 JP2018555442A JP2018555442A JP7011600B2 JP 7011600 B2 JP7011600 B2 JP 7011600B2 JP 2018555442 A JP2018555442 A JP 2018555442A JP 2018555442 A JP2018555442 A JP 2018555442A JP 7011600 B2 JP7011600 B2 JP 7011600B2
Authority
JP
Japan
Prior art keywords
bcma
fragment
subject
serum
bcma polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018555442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019508714A (ja
JP2019508714A5 (enExample
Inventor
ジェイムズ リチャード ベレンソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2019508714A publication Critical patent/JP2019508714A/ja
Publication of JP2019508714A5 publication Critical patent/JP2019508714A5/ja
Priority to JP2022004416A priority Critical patent/JP2022058619A/ja
Application granted granted Critical
Publication of JP7011600B2 publication Critical patent/JP7011600B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018555442A 2016-01-12 2017-01-12 被験体の免疫状態をモニタリングするための改善された方法 Active JP7011600B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022004416A JP2022058619A (ja) 2016-01-12 2022-01-14 被験体の免疫状態をモニタリングするための改善された方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662277801P 2016-01-12 2016-01-12
US62/277,801 2016-01-12
US201662300708P 2016-02-26 2016-02-26
US62/300,708 2016-02-26
PCT/US2017/013169 WO2017123741A1 (en) 2016-01-12 2017-01-12 Improved methods for monitoring immune status of a subject

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022004416A Division JP2022058619A (ja) 2016-01-12 2022-01-14 被験体の免疫状態をモニタリングするための改善された方法

Publications (3)

Publication Number Publication Date
JP2019508714A JP2019508714A (ja) 2019-03-28
JP2019508714A5 JP2019508714A5 (enExample) 2020-02-27
JP7011600B2 true JP7011600B2 (ja) 2022-01-26

Family

ID=59312140

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018555442A Active JP7011600B2 (ja) 2016-01-12 2017-01-12 被験体の免疫状態をモニタリングするための改善された方法
JP2022004416A Pending JP2022058619A (ja) 2016-01-12 2022-01-14 被験体の免疫状態をモニタリングするための改善された方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022004416A Pending JP2022058619A (ja) 2016-01-12 2022-01-14 被験体の免疫状態をモニタリングするための改善された方法

Country Status (6)

Country Link
US (1) US11698369B2 (enExample)
EP (2) EP3402515B8 (enExample)
JP (2) JP7011600B2 (enExample)
DK (1) DK3402515T3 (enExample)
ES (1) ES2898329T3 (enExample)
WO (1) WO2017123741A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124280A1 (en) 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
DK3402515T3 (da) 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
EP3639028B1 (en) 2017-06-13 2025-10-15 Onco Tracker, Inc. Diagnostic, prognostic, and monitoring methods for breast cancer
CN112703204B (zh) * 2018-09-28 2024-10-01 安进公司 针对可溶性bcma的抗体
CA3178882A1 (en) 2020-05-08 2021-11-11 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins and methods of use thereof
CN118206620A (zh) * 2022-12-09 2024-06-18 上海细胞治疗集团股份有限公司 一种多肽标签及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124280A1 (en) 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
JP2019501369A (ja) 2015-10-30 2019-01-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 予後法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4493795A (en) 1983-10-17 1985-01-15 Syntex (U.S.A.) Inc. Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
CA2260014A1 (en) 1996-07-10 1998-01-15 Meiji Milk Products Co., Ltd. Novel use of mk family as hematopoietic factor
GB9704444D0 (en) 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6355623B2 (en) 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2002306596B2 (en) 2001-02-27 2008-01-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
WO2003022877A1 (en) 2001-09-06 2003-03-20 Biogen Idec Ma Inc. Crystal structure of baff, and use thereof in drug design
AU2004220078A1 (en) 2003-03-07 2004-09-23 Xencor, Inc BAFF mutants with at least one amino acid substitution and methods of their production
JP5570681B2 (ja) 2004-08-31 2014-08-13 興和株式会社 抗ヒトｂａｆｆ抗体
CA2583900A1 (en) 2004-10-13 2006-04-27 The Washington University Use of baff to treat sepsis
US7947805B2 (en) * 2004-12-23 2011-05-24 Merck Serono S.A. BCMA polypeptides and uses thereof
WO2007053732A2 (en) 2005-11-01 2007-05-10 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the blys gene and use in diagnostic methods
US8202698B2 (en) 2005-11-08 2012-06-19 Biogen Idec Ma Inc. Methods of evaluating BAFF
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
SI1966202T1 (sl) 2005-12-13 2012-01-31 Incyte Corp S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze
US20080058316A1 (en) 2006-02-27 2008-03-06 The Johns Hopkins University Cancer treatment with gama-secretase inhibitors
ES2382777T3 (es) 2006-05-03 2012-06-13 Government Of The United States Of America,As Represented By The Secretary, Department Of Health And Human Services Receptor de células T quimérico y materiales relacionados y métodos de uso
EP4606378A3 (en) 2007-06-13 2025-11-05 Incyte Holdings Corporation Salts of the janus kinase inhibitor (r)-3-( 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3- cyclopentylprop anenitrile
AU2009239437B2 (en) 2008-04-25 2014-11-13 University Of Washington Levels of BCMA protein expression on B cells and use in diagnostic methods
HUE029619T4 (en) * 2009-03-10 2017-07-28 Biogen Ma Inc Anti-bcma antibodies
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
CA2833820C (en) 2011-05-27 2019-10-29 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
CA2889764C (en) * 2012-11-01 2023-10-10 Martin Lipp An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
US20160331754A1 (en) 2014-01-20 2016-11-17 Gilead Sciences, Inc. Therapies for treating cancers
KR102526945B1 (ko) 2014-04-30 2023-04-27 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Ｃｄ269에 대한 인간화 항체
EP4233870A3 (en) 2014-05-28 2024-01-24 Onco Tracker, Inc. Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
EP3154596A4 (en) 2014-06-10 2018-01-24 Institute for Myeloma & Bone Cancer Research Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid
PL3179992T3 (pl) 2014-08-11 2022-08-16 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora BTK, inhibitora PD-1 i/lub inhibitora PD-L1
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
CN113603795A (zh) 2014-12-05 2021-11-05 纪念斯隆-凯特琳癌症中心 靶向b-细胞成熟抗原的嵌合抗原受体及其用途
EP3271483B1 (en) 2015-03-17 2021-07-21 Mayo Foundation for Medical Education and Research Methods and materials for assessing and treating cancer
SG10201913841SA (en) 2015-07-24 2020-03-30 Oncotracker Inc Gamma secretase modulators for the treatment of immune system dysfunction
UA127515C2 (uk) 2015-08-17 2023-09-20 Янссен Байотек, Інк. Антитіло до всма, біспецифічна антигензв'язувальна молекула, що зв'язує всма і cd3, і їх використання
DK3402515T3 (da) 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
EP3458853B1 (en) 2016-05-16 2022-09-07 Onco Tracker, Inc. Improved methods for monitoring immune status of a subject
RU2019105693A (ru) 2016-08-01 2020-09-01 Новартис Аг Лечение рака с применением химерного антигенного рецептора в комбинации с ингибитором молекулы, способствующей фенотипу m2 макрофага
WO2018085363A2 (en) 2016-11-02 2018-05-11 Berenson James Richard Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma
EP3639028B1 (en) 2017-06-13 2025-10-15 Onco Tracker, Inc. Diagnostic, prognostic, and monitoring methods for breast cancer
JP2020528885A (ja) 2017-07-19 2020-10-01 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
WO2020092792A2 (en) 2018-10-31 2020-05-07 Oncotracker, Inc. Method of enhancing immune-based therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124280A1 (en) 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
JP2019501369A (ja) 2015-10-30 2019-01-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 予後法

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
Brian P. O’Connor，BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells，J. Exp. Med.，2004年01月05日，Vol.199 No.1，Page.91-97
Eric Sanchez，Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival，Br J Haematol，2012年07月18日，Vol.158 No.6，Page.727-738
Eric Sanchez，The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker，Expert Rev Mol Diagn，2018年03月07日，Vol.18 No.4，Page.319-329
HUNTINGTON Nicholas D，A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses，International Immunology，2006年10月，Vol.18 No.10，Page.1473-1485
Laurent Sarah A，γ-Secretase directly sheds the survival receptor BCMA from plasma cells，Nature communications，2015年06月11日，Vol.6，Page.7333
Maglione Paul J，Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies，Journal of Allergy and Clinical Immunology: In Practice，2020年01月，Vol.8 No.1，Page.283-291
Maglione, Paul J，Reduced serum BCMA levels distinguish patients with primary antibody deficiency，JOURNAL OF IMMUNOLOGY，2016年05月01日，Vol.196 Supp.1，Page.193.7
Moir, Susan，Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily，Journal of Experimental Medicine，2004年，Vol.200 No.5，Page.587-599
Rong Jin，Age-related changes in BAFF and APRIL profiles and upregulation of BAFF and APRIL expression in patients with primary antibody deficiency，Int J Mol Med，2008年02月，Vol.21 No.2，Page.233-238
Sanchez, Eric，Circulating Bcma Binding to Its Ligand BAFF Prevents Normal Antibody Production in Multiple Myeloma Patients，Blood，2014年12月06日，Vol.124 No.21，Page.4713
Sanchez, Eric，Serum Levels of B-Cell Maturation Antigen Are Elevated in Multiple Myeloma Patients and Correlate with Disease Status and Overall Survival，Blood，2012年11月16日，Vol.120 No.21，Page.4026
Sanchez, Eric，Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma，Clinical Cancer Research，2016年03月09日，Vol.22 No.13，Page.3383-3397
SHAKER Olfat G，Expression of TNF-α, April and BCMA in Behcet's Disease，Journal of Immunology Research，2014年11月05日，Vol.2014，Page.380405

Also Published As

Publication number Publication date
EP3402515B8 (en) 2021-12-08
JP2022058619A (ja) 2022-04-12
US20190049437A1 (en) 2019-02-14
JP2019508714A (ja) 2019-03-28
ES2898329T3 (es) 2022-03-07
EP3402515A4 (en) 2019-07-10
EP4079320A1 (en) 2022-10-26
CA3010019A1 (en) 2017-07-20
WO2017123741A1 (en) 2017-07-20
EP3402515A1 (en) 2018-11-21
DK3402515T3 (da) 2021-11-15
US11698369B2 (en) 2023-07-11
EP3402515B1 (en) 2021-08-11

Similar Documents

Publication Publication Date Title
US12174189B2 (en) Diagnostic, prognostic, and monitoring methods for chronic lymphocytic leukemia
JP2022058619A (ja) 被験体の免疫状態をモニタリングするための改善された方法
JP6861771B2 (ja) 腎疾患のためのマーカー
EP3458853B1 (en) Improved methods for monitoring immune status of a subject
US20180113127A1 (en) Immunoassay method and assay reagent used in said method
KR102431142B1 (ko) L-fabp의 면역학적 측정 방법 및 해당 방법에 사용되는 측정 시약
US11635435B2 (en) Diagnostic, prognostic, and monitoring methods for solid tumor cancers
HK40082699A (en) Improved methods for monitoring immune status of a subject
CA3010019C (en) Improved methods for monitoring immune status of a subject
WO2018085363A2 (en) Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma
HK40000182B (en) Improved methods for monitoring immune status of a subject
HK40007456B (en) Improved methods for monitoring immune status of a subject
HK40007456A (en) Improved methods for monitoring immune status of a subject
KR101567053B1 (ko) 방사선 피폭에 의한 간 손상 예측용 바이오마커 및 그 예측방법
JP7066142B2 (ja) 試料に含まれるペリオスチン測定の感度の改善方法
JP2013096783A (ja) 肺腺癌を判定するためのデータ検出方法、診断薬、及び診断用キット
TWI363763B (en) The measuring method for human orotate phosphoribosyl transferase protein
JPWO2018143336A1 (ja) 膵臓癌の検査方法
JP2017106884A (ja) 甲状腺刺激ホルモンレセプター抗体アイソタイプ測定を用いたバセドウ病の病態診断キット及びバセドウ病の病態の診断方法
JP2024043214A (ja) イヌｈｅｒ２の検出方法
CN117178190A (zh) 用于检测sars-cov-2的测定

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200114

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211215

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220114

R150 Certificate of patent or registration of utility model

Ref document number: 7011600

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250